Treatment of children with langerhans cell histiocytosis with 2-chlorodeoxyadenosine

American Journal of Hematology

Volumn 69, Issue 3, 2002, Pages 179-184

  Rodriguez Galindo, Carlos ^a   Kelly, Patrick ^a   Jeng, Michael ^a   Presbury, Gerald G ^b   Rieman, Martha ^a   Wang, Winfred ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

2 Chlorodeoxyadenosine; Children; Langerhans cell histiocytosis

Indexed keywords

CLADRIBINE; PURINE DERIVATIVE;

ARTICLE; BLOOD TOXICITY; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HIGH RISK PATIENT; HISTIOCYTOSIS; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; LANGERHANS CELL; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; TREATMENT OUTCOME;

CHILD; CHILD, PRESCHOOL; CLADRIBINE; COHORT STUDIES; DISEASE-FREE SURVIVAL; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 0036179160     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10053     Document Type: Article

References (45)

1. Clinical aspects of Langerhans cell histiocytosis
2. Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis
3. Langerhans' cell histiocytosis (histiocytosis X) - A clonal proliferative disease
4. Spontaneous remission of multisystem histiocytosis X
5. Cyclosporine therapy for advanced Langerhans cell histiocytosis
6. Langerhans cell histiocytosis in childhood: Results from the Italian Cooperative
7. Treatment strategy for disseminated Langerhans cell histiocytosis
8. Current therapy for Langerhans cell histiocytosis
9. Oral methotrexate and alternate-day prednisone for low-risk Langerhans cell histiocytosis
10. LCH-I: A randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis
11. Cyclosporine therapy for refractory Langerhans cell histiocytosis
12. Marrow transplantation for treatment of multisystem progressive Langerhans cell histiocytosis
13. 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis
14. Cladribine activity in adult Langerhans-cell histiocytosis
15. 2-Chlorodeoxyadenosine (2-CDA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients
16. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: A survey of members of the Histiocyte Society and review of the literature
17. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant lymphoblasts in vitro and toward murine L1210 leukemia in vivo
18. Clinical and toxicological aspects of the antineoplastic drug cladribine: A review
19. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoietic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice
20. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine
21. The scripps clinic experience with cladribine (2-CdA) in the treatment of chronic lymphocytic leukemia
22. Cladribine for the treatment of indolent non-Hodgkin's lymphomas
23. Treatment of hairy-cell leukemia with 2-chlorodeoxyadenosine (2-CdA)
24. Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine
25. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia
26. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes
27. New chemotherapeutic agent: 2-Chlorodeoxyadenosine
28. A phase I clinical of 2-chlorodeoxyadenosine in pediatric patients with acute leukemia
29. Cellular pharmacokinetics of 2-chloro-2′-deoxyadenosine nucleotides: Comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients
30. Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies
31. Expression of deoxycytidine kinase and phosphorylation of 2-chlorodeoxyadenosine in human and tumour cells and tissues
32. Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo
33. Treatment of Langerhans cell histiocytosis with 2-chlorodeoxyadenosine
34. Successful treatment of two children with Langerhans' cell histiocytosis with 2′-deoxycoformycin
35. 2′-Deoxycoformycin as treatment in refractory Langerhans cell histiocytosis
36. Langerhans' cell histiocytosis cells are activated Langerhans' cells
37. Defective alloantigen-presenting capacity of Langerhans cell histiocytosis cells
38. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis
39. Langerhans cell histiocytosis in children: Does soluble Interleukin-2-receptor correlate with both disease extent and activity?
40. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: Phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine
41. 4- lymphocyte counts in patients with hairy-cell leukemia
42. Severe immunodeficiency in patients treated with fludarabine monophosphate
43. Infectious complications after 2-chlorodeoxyadenosine therapy
44. Treatment of multiple sclerosis and other autoimmune diseases with cladribine
45. Disease course and late sequelae of Langerhans' cell histiocytosis: 25-Year experience at the University of California, San Francisco